ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
Company: ENDRA Life Sciences Inc.
Filing Date: June 28, 2018 (Reported Event Date)
Reporting Period: Current Report on Form 8-K
Context: The Company, an emerging growth company, announced the closing of a private placement offering to raise capital through the sale of senior secured convertible promissory notes and warrants.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $1.1 million.
- Principal Amount of Notes: $1,077,000.
- Interest Rate: 10% per annum (increases to 15% upon an Event of Default).
- Maturity Date: December 31, 2018.
- Warrants Issued: Warrants exercisable for 267,113 shares of Common Stock to investors; 53,423 shares to the Placement Agent.
- Warrant Exercise Price: $2.52 per share.
- Placement Agent Fees: 10% commission of gross proceeds plus $34,000 in reimbursed expenses.
- Collateral: Notes are secured by a first priority lien on substantially all of the Company's assets.
Material Changes and Terms
This filing represents a material change in the Company's capital structure and debt obligations. Key terms include:
- Conversion Price: The lesser of (a) the lowest price in a Qualified Financing less a 20% discount, or (b) $2.016, with a floor of $1.40.
- Automatic Conversion: Notes automatically convert upon a "Qualified Financing" (sale of Common Stock resulting in at least $7.0 million in gross cash proceeds).
- Registration Rights: The Company agreed to file a registration statement within 45 days. Failure to do so triggers penalty payments of 1.0% of the invested amount per 30-day period.
- Lock-up: Investors agreed not to sell shares underlying the securities for 90 days following the effective date of a registration statement for a Qualified Financing.
Outlook, Risks, and Contingencies
- Liquidity Risk: The short maturity date (December 31, 2018) creates a refinancing or conversion requirement within six months of issuance.
- Dilution Risk: Significant potential dilution exists due to the low conversion price floor ($1.40) and the issuance of warrants.
- Default Risk: An Event of Default triggers an immediate acceleration of the debt and an interest rate increase to 15%.
- Asset Encumbrance: Substantially all Company assets are now pledged as collateral for this debt.
- Regulatory Contingency: The Company faces financial penalties if it fails to file the required registration statement within 45 days.
Investor Verification Checklist
- Verify the Company's current cash position and ability to service the 10% interest payments due quarterly.
- Confirm the status of the registration statement filing required within 45 days of June 28, 2018.
- Assess the likelihood of a "Qualified Financing" ($7.0 million) occurring before the December 31, 2018 maturity date.
- Review the extent of assets pledged under the Security Agreement to understand remaining unencumbered assets.
- Check for any subsequent filings regarding the conversion of notes or extension of the maturity date.